Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 994 of 994 entries
View as:

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02114931 Org: User:
Start: 04/30/14 End: 04/30/16 Due: 04/30/17

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

Phase: N/A Priority: Normal
NCT ID: NCT04762498 Org: User:
Start: 01/26/21 End: 12/20/23 Due: 12/20/24

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01695876 Org: User:
Start: 10/31/12 End: 10/31/14 Due: 10/31/15

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Phase: N/A Priority: Normal
NCT ID: NCT02322736 Org: User:
Start: 11/21/14 End: 08/03/18 Due: 08/03/19

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Phase: N/A Priority: Normal
NCT ID: NCT02910557 Org: User:
Start: 08/10/17 End: 01/07/38 Due: 01/07/39

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

Phase: N/A Priority: Normal
NCT ID: NCT01901185 Org: User:
Start: 06/11/13 End: 12/30/13 Due: 12/30/14

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT02994927 Org: User:
Start: 03/15/17 End: 11/01/19 Due: 11/01/20

Observational Study of Blinatumomab

Phase: N/A Priority: Normal
NCT ID: NCT03117621 Org: User:
Start: 03/22/17 End: 03/20/24 Due: 03/20/25

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT01785849 Org: User:
Start: 03/12/13 End: 06/12/14 Due: 06/12/15

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01987232 Org: User:
Start: 11/05/13 End: 05/04/17 Due: 05/04/18

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Phase: N/A Priority: Normal
NCT ID: NCT05002998 Org: User:
Start: 09/16/21 End: 04/15/26 Due: 04/15/27

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT05672199 Org: User:
Start: 04/28/23 End: 10/31/24 Due: 10/31/25

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT01331941 Org: User:
Start: 09/19/11 End: - Due: -

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT02186171 Org: User:
Start: 06/16/14 End: 04/20/16 Due: 04/20/17

Study of Erenumab (AMG 334) in Women With Hot Flashes

Phase: N/A Priority: Normal
NCT ID: NCT01890109 Org: User:
Start: 05/13/13 End: 03/11/14 Due: 03/11/15

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

Phase: N/A Priority: Normal
NCT ID: NCT02347865 Org: User:
Start: 06/16/15 End: 09/27/18 Due: 09/27/19

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Phase: N/A Priority: Normal
NCT ID: NCT06122649 Org: User:
Start: 11/27/23 End: 12/07/25 Due: 12/07/26

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05571163 Org: User:
Start: 03/06/20 End: 06/14/20 Due: 06/14/21

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Phase: N/A Priority: Normal
NCT ID: NCT02509507 Org: User:
Start: 02/05/16 End: 07/11/23 Due: 07/11/24